Photo via CNBC Business
CVS Health announced plans to expand its coverage of popular obesity treatments, restoring access to Novo Nordisk's Zepbound while simultaneously adding Eli Lilly's newly approved Foundayo to its drug formularies. According to CNBC Business, Zepbound coverage will resume on October 1, while Foundayo will be added to CVS plans beginning June 1. The moves represent a significant shift in insurer willingness to cover these high-demand weight-loss medications.
The decision to restore Zepbound coverage comes after CVS had previously restricted access to the medication. By adding both Novo Nordisk and Eli Lilly's obesity treatments to its formularies, CVS is signaling confidence in the growing class of GLP-1 receptor agonist drugs. These medications have generated substantial consumer interest and physician demand since their approval, though coverage decisions have remained inconsistent across major health insurers.
For Dallas-area employers and healthcare providers, CVS's expanded coverage could significantly impact benefit design decisions and patient access to these medications. With CVS being a major pharmacy benefit manager serving numerous Texas-based companies and health plans, this policy change may influence how local employers structure their prescription drug benefits and negotiate rates for obesity treatments in 2024 and beyond.
The expansion of obesity drug coverage among major insurers reflects broader industry recognition of GLP-1 medications' clinical value and market demand. As competition intensifies between Novo Nordisk and Eli Lilly for market share, insurer decisions like CVS's will likely continue shaping patient access patterns and treatment pathways across the healthcare landscape.
